Stem Cells, Differation and Cancer Program

干细胞，分化和癌症计划从以前的细胞生长和分化发展而来 控制计划，包括研究B细胞生物学的前免疫肿瘤学计划的科学家 和淋巴恶性肿瘤。该计划得到了进一步加强，成立了一个干细胞研究所， 爱因斯坦招募了四名癌症干细胞研究人员。有三个主要的研究主题， 部分重叠：骨髓性白血病，淋巴恶性肿瘤和干细胞生物学，并继续强调 在转录水平上的调节。虽然关注血液恶性肿瘤，但干细胞 研究扩展到肝脏、神经和乳腺干细胞。Dr. E.理查德·斯坦利是这个新的 配置的程序。医生科学家Amit Verma博士被任命为联合项目负责人， 血液肿瘤工作组的成立促进了翻译， 相关和治疗性临床研究的数量。该计划的目标是：（一）了解 在干细胞祖细胞正常分化成其成熟对应物期间发生的分子事件; (ii)为了鉴定在转录编程中发生的导致恶性表型的畸变， 特别的，但不是唯一的，专注于造血系统恶性肿瘤;（iii）鉴定新的治疗分子， 目标、疾病侵袭性的指标或对治疗反应的报告者;（iv）将实验室 研究结果转化为相关的，最终，治疗性试验，并提高临床治疗的有效性。 现有的和新的化疗药物和生物制剂的治疗方案;以及（v）鼓励这些计划成员 他们在干细胞、细胞编程及其与癌症的关系方面有着共同的兴趣， 以及其他项目的成员之间的关系人体组织研究得到了 收购了两个专门用于该计划的FACS分选仪生物安全系统，一个人类多能干细胞 人类胚胎和诱导多能干细胞的开发和分析中心， 干细胞制备单元、细胞分选和异种移植单元以及干细胞生物信息学单元。有 目前有31名项目成员，其中30人是小学生，9人是爱因斯坦的新成员。研究得到支持 由12个NCI赠款（266万美元DC）和28个其他癌症相关的同行评审赠款（535万美元DC）。自2008年以来， 该计划成员发表了364篇与癌症相关的出版物，其中16%代表内部，17%代表 代表方案间合作。

The Stem Cells, Differentiation and Cancer Program evolved from the former Cell Growth and Differentiation Control Program with the inclusion of scientists from the former Immuno-oncology program that study B cell biology and lymphoid malignancies. The program was further strengthened by the formation of a Stem Cell Institute at Einstein with the recruitment of four cancer stem cell investigators. There are three major research themes that partially overlap: the myeloid leukemias, lymphoid malignancies and stem cell biology, with a continued emphasis on regulation at the transcriptional level. While there is a focus on hematological malignancies, the stem cell research extends to hepatic, neural, and mammary stem cells. Dr. E. Richard Stanley is leader of this newly configured program. The appointment of Dr. Amit Verma, physician scientist, as Co-Program leader and the establishment of a Hematological Malignancies Working Group has catalyzed translation and increased the number of correlative and therapeutic clinical studies. The goals of this program are: (i) to understand the molecular events that occur during the normal differentiation of stem cell progenitors into their mature counterparts; (ii) to identify the aberrations that occur in transcriptional programming that result in the malignant phenotype with a special, but not sole, focus on the hematopoietic malignancies; (iii) to identify molecules that are novel therapeutic targets, indicators of aggressiveness of disease or reporters of response to treatment; (iv) to translate laboratory research findings into correlative and, ultimately, therapeutic trials and to enhance the effectiveness of clinical regimens with existing and new chemotherapeutics and biologicals; and (v) to encourage those Program members who share a common interest in stem cells, cellular programming, and their relationship to cancer to collaborate with each other and with the members of other programs. Human tissue research has been facilitated by the acquisition of two FACS Sorter Biosafety systems dedicated to this program, a Human Pluripotent Stem Cell Center for the development and analysis of human embryonic and induced pluripotent stem cells that comprises a stem cell preparation unit, a cell sorting and xenotransplantation unit, and a stem cell bioinformatics unit. There are currently 31 program members of whom 30 are primary; nine are new recruits to Einstein. Research is supported by 12 NCI grants ($2.66M DC) and 28 other cancer-relevant peer reviewed grants ($5.35M DC). Since 2008, there have been 364 cancer-relevant publications by members of this program, of which 16% represent intra- and 17% represent inter-programmatic collaborations.